新型药物时代自体移植后复发或难治性霍奇金淋巴瘤的结局改善
该研究比较了2011至2020年(183例)与2001至2010年(159例)在本机构接受自体造血细胞移植的复发或难治性经典型霍奇金淋巴瘤患者,发现现代期总生存更优,移植后进展患者的4年进展后生存从43.3%升至71.4%,与维布妥昔单抗和PD-1抑制剂使用增加有关。
要点
- 现代期自体移植后总生存优于早期,移植2年后非复发死亡有降低趋势。
- 移植后进展患者4年进展后生存从43.3%升至71.4%,反映维布妥昔单抗和PD-1抑制剂使用增加。
- 移植前PD-1抑制剂为基础的方案与更优无进展生存相关。
核心结论
- 现代期复发或难治性经典型霍奇金淋巴瘤患者自体造血细胞移植后生存改善,归因于更有效的挽救方案使移植前疾病控制更好以及移植后进展患者结局改善。
- 移植前PD-1抑制剂为基础的挽救方案观察到优异结局,支持在二线治疗中开展评估免疫治疗的随机试验。
研究设计与样本
- 单中心研究,比较2011至2020年接受自体造血细胞移植的复发或难治性经典型霍奇金淋巴瘤患者(N=183)与2001至2010年患者(N=159)。
- 评估两个时代的结局与实践模式变化,并分析无进展生存和总生存的预后因素。
主要发现
- 现代期总生存更优,移植2年后非复发死亡有降低趋势。
- 移植后进展患者4年进展后生存从43.3%增至71.4%,反映维布妥昔单抗和PD-1抑制剂使用增加。
- 现代期移植患者多变量分析中,年龄≥45岁、原发难治性疾病、自体移植前未达完全缓解与更差无进展生存相关,移植前接受PD-1抑制剂为基础的方案与更优无进展生存相关。
- 复发时结外病变与更差总生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved significantly over the past decade after the approval of brentuximab vedotin (BV) and the programmed death-1 (PD-1) inhibitors. We evaluated how outcomes and practice patterns have changed for patients with R/R cHL who underwent autologous hematopoietic cell transplantation (AHCT) at our institution from 2011 to 2020 (N = 183) compared with those from 2001 to 2010 (N = 159) and evaluated prognostic factors for progression-free survival (PFS) and overall survival (OS) in both eras. OS was superior in the modern era with a trend toward lower nonrelapse mortality beyond 2 years after transplant. Among patients who progressed after AHCT, 4-year postprogression survival increased from 43.3% to 71.4% in the modern era, reflecting increasing use of BV and the PD-1 inhibitors. In multivariable analysis for patients that underwent transplant in the modern era, age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT were associated with inferior PFS, whereas receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS. Extranodal disease at relapse was associated with inferior OS. Our study demonstrates improved survival for R/R cHL after AHCT in the modern era attributed to more effective salvage regimens allowing for better disease control pre-AHCT and improved outcomes for patients who progressed after AHCT. Excellent outcomes were observed with PD-1 inhibitor-based salvage regimens pre-AHCT and support a randomized trial evaluating immunotherapy in the second line setting.
引用
- Spinner MA, Sica RA, Tamaresis JS, et al. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023. PMID: 36857637. doi:10.1182/blood.2022018827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。